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Since diphtheria toxin was isolated by Roux
and Yersin in 1888 (1), microbial toxins have
been recognized as the primary virulence
factor(s) for a variety of pathogenic bacteria.
Bacterial toxins have been defined as soluble
substances that alter the normal metabolism of
host cells with deleterious effects on the host (2).
Indeed, the major symptoms associated with
disease caused by Corynebacterium diphtheriae
(diphtheria),  Bordetella pertussis (whooping
cough), Vibrio cholerae (cholera), Bacillus
anthracis (anthrax), Clostridium botulinum
(botulism),  Clostridium tetani (tetanus), and
enterohemorrhagic  Escherichia coli (bloody
diarrhea and hemolytic uremic syndrome) are all
related to the activities of the toxins produced by
these organisms. With the recognition of the
central role of toxin in these and other diseases
has come the application of inactive toxins
(toxoids) as vaccines. Such toxoid vaccines have
had an important positive impact on public
health.
In this review, we provide a summary
overview (Table) of a variety of bacterial toxins
categorized according to mode of action:
damaging cell membranes, inhibiting protein
synthesis, activating second messenger path-
ways, inhibiting the release of neurotransmit-
ters, or activating the host immune response. We
also describe in detail seven toxins: Staphylococ-
cus aureus a-toxin, Shiga toxin (Stx), cytotoxic
necrotizing factor type 1 (CNF1), E. coli heat-
stable toxin (ST), botulinum and tetanus
neurotoxins, and toxic-shock syndrome toxin
(TSST) produced by S. aureus. We emphasize
these toxins because they are produced by
emerging (Stx of enterohemorrhagic E. coli) or
reemerging (a-toxin of multidrug-resistant
S. aureus) pathogens or illustrate different
structures or modes of action (ST, CNF1,
neurotoxins, and TSST).
When It Rains, It Pores
Many bacterial exotoxins have the capacity
to damage the extracellular matrix or the plasma
membrane of eukaryotic cells. The damage not
only may result in the direct lysis of cells but also
can facilitate bacterial spread through tissues.
Toxins that mediate this cellular damage do so by
either enzymatic hydrolysis or pore formation.
Bacterial hyaluronidases, collagenases, and
phospholipases have the capacity to degrade
cellular membranes or matrices. Specific
examples of these types of toxins include the
a-toxin of Clostridium perfringens, which has
phospholipase C activity; Streptococcus pyogenes
streptokinase, which can hydrolyze plasminogen
to plasmin and dissolve clots; and the clostridial
collagenases (3-5). Pore-forming toxins, as the
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Table. Characteristics of bacterial toxinsa
Toxin implicated
Organism/toxin Mode of action Target Disease        in diseaseb
Damage membranes
  Aeromonas hydrophila/aerolysin Pore-former Glycophorin Diarrhea (yes)
  Clostridium perfringens/ Pore-former Cholesterol Gas gangrenec   ?
    perfringolysin O
  Escherichia coli/hemolysind Pore-former Plasma membrane UTIs (yes)
  Listeria monocytogenes/ Pore-former Cholesterol Foodborne systemic (yes)
    listeriolysin O   illness,  meningitis
  Staphyloccocus aureus/a-toxin Pore-former Plasma membrane Abcessesc (yes)
  Streptococcus pneumoniae/ Pore-former Cholesterol Pneumoniac (yes)
    pneumolysin
  Streptococcus pyogenes/ Pore-former Cholesterol Strep throat, Sfc   ?
    streptolysin O
Inhibit protein synthesis
  Corynebacterium diphtheriae/ ADP-ribosyltransferase Elongation factor 2 Diphtheria yes
    diphtheria toxin
  E. coli/Shigella dysenteriae/ N-glycosidase 28S rRNA HC and HUS yes
    Shiga toxins
  Pseudomonas aeruginosa/ ADP-ribosyltransferase Elongation factor 2 Pneumoniac (yes)
    exotoxin A
Activate second messenger
pathways
  E.coli
    CNF Deamidase Rho G-proteins UTIs   ?
    LT ADP-ribosyltransferase G-proteins Diarrhea yes
    STd Stimulates guanylate cyclase Diarrhea yes
  guanylate cyclase   receptor
    CLDTd G2 block Unknown Diarrhea (yes)
    EAST ST-like? Unknown Diarrhea   ?
  Bacillus anthracis/edema factor Adenylate cyclase ATP Anthrax yes
  Bordetella pertussis/
    dermonecrotic toxin Deamidase Rho G-proteins Rhinitis (yes)
    pertussis toxin ADP-ribosyltransferase G-protein(s) Pertussis yes
  Clostridium botulinum/C2 toxin ADP-ribosyltransferase Monomeric G-actin Botulism   ?
  C. botulinum/C3 toxin ADP-ribosyltransferase Rho G-protein Botulism   ?
  Clostridium difficile/
    toxin A Glucosyltransferase Rho G-protein(s) Diarrhea/PC (yes)
    toxin B Glucosyltransferase Rho G-protein(s) Diarrhea/PC   ?
  Vibrio cholerae/cholera toxin ADP-ribosyltransferase G-protein(s) Cholera yes
Activate immune response
  S. aureus/
    enterotoxins Superantigen TCR and MHC II Food poisoningc yes
    exfoliative toxins Superantigen (and TCR and MHC II SSSc yes
  serine  protease?)
    toxic-shock toxin Superantigen TCR and MHC II TSSc yes
  S. pyogenes/pyrogenic exotoxins Superantigens TCR and MHC II SF/TSSc yes
Protease
  B. anthracis/lethal factor Metalloprotease MAPKK1/MAPKK2 Anthrax yes
  C. botulinum/neurotoxins A-G Zinc-metalloprotease VAMP/synaptobrevin, Botulism yes
  SNAP-25, syntaxin
  Clostridium tetani/tetanus toxin Zinc-metalloprotease VAMP/synaptobrevin Tetanus yes
aAbbreviations: CNF, cytotoxic necrotizing factor; LT, heat-labile toxin; ST, heat-stable toxin; CLDT, cytolethal distending toxin;
EAST, enteroaggregative E. coli heat-stable toxin; TCR, T-cell receptor; MHC II, major histocompatibility complex class II;
MAPKK, mitogen-activated protein kinase kinase; VAMP, vesicle-associated membrane protein; SNAP-25, synaptosomal-
associated protein; UTI, urinary tract infection; HC, hemorrhagic colitis; HUS, hemolytic uremic syndrome; PC, antibiotic-
associated pseudomembranous colitis; SSS, scalded skin syndrome; SF, scarlet fever; TSS, toxic-shock syndrome.
bYes, strong causal relationship between toxin and disease; (yes), role in pathogenesis has been shown in animal model or
appropriate cell culture; ?, unknown.
cOther diseases are also associated with the organism.
dToxin is also produced by other genera of bacteria.226 Emerging Infectious Diseases Vol. 5, No. 2, AprilJune 1999
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Figure 1. Diagrammatic representation of the mode of action of several bacterial toxins. A. Damage to cellular
membranes by Staphylococcus aureus a-toxin. After binding and oligomerization, the stem of the mushroom-
shaped a-toxin heptamer inserts into the target cell and disrupts membrane permeability as depicted by the
influx and efflux of ions represented by red and green circles. B. Inhibition of protein synthesis by Shiga toxins
(Stx). Holotoxin, which consists of an enzymatically active (A) subunit and five binding (B) subunits, enters cells
through the globotriasylceramide (Gb3) receptor. The N-glycosidase activity of the A subunit then cleaves an
adenosine residue from 28S ribosomal RNA, which halts protein synthesis. C. Examples of bacterial toxins that
activate secondary messenger pathways. Binding of the heat-stable enterotoxins (ST) to a guanylate cyclase
receptor results in an increase in cyclic GMP (cGMP) that adversely effects electrolyte flux. By ADP-
ribosylation or glucosylation respectively, the C3 exoenzyme (C3) of Clostridium botulinum and the Clostridium
difficile toxins A and B (CdA & CdB) inactivate the small Rho GTP-binding proteins. Cytotoxic necrotizing
factor (CNF) of E. coli and the dermonecrotic toxin (DNT) of Bordetella species activate Rho by deamidation.
name suggests, disrupt the selective influx and
efflux of ions across the plasma membrane by
inserting a transmembrane pore. This group of
toxins includes the RTX (repeats in toxin) toxins
from gram-negative bacteria, streptolysin O
produced by S. pyogenes, and the S. aureus
a-toxin (described below).
S. aureus a-toxin can be considered the
prototype of oligomerizing pore-forming cytotox-
ins. The a-toxin gene resides as a single copy on
the chromosome of most pathogenic S. aureus
strains, and its expression is environmentally
regulated at the transcriptional level by the
staphylococcal accessory gene regulator (agr)
locus (6,7). The a-toxin is synthesized as a 319
amino acid precursor molecule that contains an
N-terminal signal sequence of 26 amino acids.
The secreted mature toxin, or protomer, is a
hydrophilic molecule that lacks cysteine resi-
dues and has a molecular mass of approximately
33 kDa (6-8). Recently, the crystallographic
structure of the fully assembled  a-toxin pore was
solved (9). On the plasma membrane, seven toxin
protomers assemble to form a 232-kDa mush-
room-shaped heptamer comprising three distinct
domains (Figure 1A) (9,10). The cap and rim227 Vol. 5, No. 2, AprilJune 1999 Emerging Infectious Diseases
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domains of the a-toxin heptamer are situated at
the surface of the plasma membrane, while the
stem domain serves as the transmembrane
channel.
Alpha-toxin is cytolytic to a variety of cell
types, including human monocytes, lympho-
cytes, erythrocytes, platelets, and endothelial
cells (6,8). For a-toxin to damage cellular
membranes, three sequential events are re-
quired. Toxin protomers must first bind to target
membranes by either unidentified high-affinity
receptors or through nonspecific absorption to
substances such as phosphotidylcholine or
cholesterol on the lipid bilayer (6-8). Second,
membrane-bound protomers must oligomerize
into a nonlytic prepore heptamer complex. Third,
the heptamer must undergo a series of
conformational changes that create the stem
domain of the toxin, which is then inserted into
the membrane (9,10). The a-toxin pore allows the
influx and efflux of small molecules and ions that
eventually lead to the swelling and death of
nucleated cells and the osmotic lysis of
erythrocytes. Pore formation has also been
shown to trigger secondary events that could
promote development of pathologic sequelae.
These events include endonuclease activation,
increased platelet exocytosis, release of cytokines
and inflammatory mediators, and production of
eicosanoids (6,8). Several animal models have
demonstrated that a-toxin is required for
S. aureus virulence in these systems (6,8);
however, the precise role of a-toxin in
staphylococcal diseases in humans remains
unclear.
Stop, in the Name of Toxin
A second class of toxins intoxicates target
cells by inhibiting protein synthesis. Substrates
for toxins in this group are elongation factors and
ribosomal RNA. Diphtheria toxin and Pseudomo-
nas exotoxin A act by ADP-ribosylating
elongation factor 2 (EF2) (11,12). The modified
EF2 is no longer able to function in protein
synthesis. Stxs, also called verotoxins, are
produced by Shigella dysenteriae serotype 1 and
the emerging pathogens designated Stx-produc-
ing  E. coli (STEC). Stxs inactivate ribosomal
RNA (by a mechanism described below) so that
the affected ribosome can no longer interact with
elongation factors (13,14). The inhibition of
protein synthesis by this group of toxins
ultimately results in death of the target cell.
Stxs are potent cytotoxins that can be
divided into two antigenically distinct groups
that share 50% to 60% homology: Stx/Stx1 and
Stx2 (15-17). Stx and Stx1 are elaborated by
S. dysenteriae serotype 1 and E. coli,
respectively, and differ at only one amino acid.
Stx2-type toxins have been found only in E. coli
isolates and are quite diverse. While Stx2 is
considered the prototype of this group, variants
have been found that differ antigenically, in
receptor specificity and in activation by
intestinal mucus. Some of these attributes are
the result of only one or two nucleotide
differences in the toxin genes.
The  stx  of  S. dysenteriae is invariably
chromosomally located. The genes that encode
Stx1 and Stx2 are carried chromosomally or by
lysogenic bacteriophages. The genes that code
for the A and B subunits of Stxs, stxA and stxB,
are organized within an operon. The operator
region of Stx/Stx1 (but not Stx2) contains a
consensus fur box that is responsible for the iron-
regulation of Stx and Stx1 production. Neither
iron nor any other environmental factors
examined affect the expression of Stx2. However,
intestinal mucus enhances the activity of some
Stx2 variants (18). The Stxs, which carry typical
N-terminal leader sequences, are not actively
secreted from the bacterial cell and are thought
to be released into the milieu during cell lysis.
Stxs display an AB-toxin structure; an
enzymatically active A subunit is noncovalently
associated with a binding, or B, component. The
crystal structures of the Stx1 B pentamer (19)
and the Stx holotoxin have been solved (20)
(Figure 2). Other toxins that share this AB
structure are the E. coli heat-labile toxin (21),
cholera toxin, and pertussis toxin (22) (Figure 2).
The molecular masses of mature Stx A and B
monomeric subunits are approximately 35 kDa
and 7.5 kDa, respectively, although holotoxin
contains five B subunit molecules. The B subunit
pentamer directs the binding of the holotoxin to
sensitive eukaryotic cells via specific glycolipid
receptors. Once internalized, the A polypeptide
is cleaved into an enzymatically active A1 portion
and an A2 portion; these fragments remain
associated through a disulfide bond. The A2
portion serves to link the A1 fragment and the B
pentamer.
The enzymatic A subunit acts as a
specific  N-glycosidase to cleave a single adenine
residue from 28S ribosomal RNA (13,14). This228 Emerging Infectious Diseases Vol. 5, No. 2, AprilJune 1999
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Figure 2. Ribbon crystal structures of Shigella dysenteriae Shiga toxin (20), Escherichia coli heat-labile toxin I
(LT-I) (21), and pertussis toxin (22). The Shiga toxin figure was contributed by Marie Frasier. The LT-I and
pertussis figures were contributed by Ethan Merritt. The figures were drawn in MOLSCRIPT (75).
depurination ultimately results in the inhibition
of protein synthesis within intoxicated cells
(Figure 1B). Prokaryotic ribosomes are as
sensitive to the N-glycosidase activity of Stx as
eukaryotic ribosomes (23).
STEC are considered emerging pathogens
(24) because they were first described less than
20 years ago, during a 1983 outbreak of
hemorrhagic colitis associated with undercooked
hamburger (25,26). STEC O157:H7 causes
approximately 20,000 cases of hemorrhagic
colitis each year in the United States (27).
Approximately 1,000 cases of the life-threaten-
ing sequelae hemolytic uremic syndrome and
approximately 100 deaths are also attributed to
E. coli O157:H7 annually in the United States (27).
Don’t Shoot the Messenger
Bacterial toxins can also target and alter the
function of a variety of cellular proteins without
directly killing the intoxicated cell. Toxin
activation or modification of secondary messen-
gers can cause dramatic alterations to signal
transduction pathways critical in maintaining a
variety of cellular functions. To demonstrate the
diversity among the toxins that belong to this
category, we will describe CNF type 1 and the
heat-stable enterotoxins.
Cytotoxic Necrotizing Factor (CNF)
CNF types 1 and 2 (CNF1/2) from E. coli
belong to a group of bacterial toxins that modify
Rho, a subfamily of small GTP-binding proteins
that are regulators of the actin cytoskeleton
(28,29). Most members of this toxin family, which
includes the large clostridial cytotoxins and the
C3 exoenzyme of C. botulinum, inactivate Rho
(29). CNF1, CNF2, and the dermonecrotic toxins
from Bordetella species form a unique subset in
this family, since these toxins have the capacity
to activate Rho (Figure 1C) (29-32). CNF1 and
CNF2 share 99% amino acid similarity; however,
we will discuss only CNF1 in detail because of
its association with extraintestinal E. coli
infections in humans, most notably urinary
tract infections.
The gene for CNF1 is chromosomally
encoded and resides on a pathogenicity island in
uropathogenic  E. coli (33,34). The toxin is
synthesized as a hydrophilic polypeptide of
approximately 115 kDa that remains primarily
cytoplasmic because of the lack of a signal
sequence (33). Recent structure and function
analysis of CNF1 indicates that the toxin has
distinct binding and enyzmatic domains (35).
The N-terminal half of CNF1, which includes two
potential transmembrane domains, contains the
cellular binding domain. This region of the
molecule shows amino acid similarity to the
Pasteurella multicoda toxin, a potent mitogen
thought to be the etiologic agent of progressive
atrophic rhinitis in pigs (33,35). The C-terminal
portion of CNF1 represents the toxins enzymatic
domain and shows homology with dermonecrotic
toxins in a 100-amino acid stretch that may
represent the active site of the toxin (33,35).229 Vol. 5, No. 2, AprilJune 1999 Emerging Infectious Diseases
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Figure 3. The effect of cytotoxic necrotizing factor type
1 (CNF1) on eukaryotic cells. A. HEp-2 cells,
magnification 10X. B. HEp-2 cells intoxicated with
CNF1, magnification 10X.
Eukaryotic cells intoxicated with CNF1
exhibit membrane ruffling; the formation of focal
adhesions and actin stress fibers; and DNA
replication in the absence of cell division, a
phenomenon that results in enlarged multi-
nucleated cells (Figure 3). The drastic changes
apparent in CNF1-treated cells are a result of the
toxins capacity to modify Rho (29,30,32). This
modification has recently been identified as a
deamidation of the glutamine residue at position
63 of Rho to a glutamic acid. This amino acid
change produces a dominant active Rho protein
unable to hydrolyze bound GTP (30,32). In vivo,
CNF1 causes necrosis in rabbit skin following
intradermal injection and persistent inflamma-
tion in a mouse footpad assay (36). Epidemiologic
data support the role of CNF1 as a virulence
factor in human extraintestinal infections,
although direct proof of the toxins role in disease
remains to be determined (29,37).
Heat-Stable Toxin (ST)
Two families of diarrheagenic STs have been
described: STa (or STI) and STb (or STII).
Distinct STas are produced by a variety of
enteric pathogenic organisms: enterotoxinogenic
E. coli (ETEC) (the focus of this section),
V. cholerae, Vibrio mimicus, Yersinia
enterocolitica,  Citrobacter freundii, and Kleb-
siella.
Strains of ETEC associated with human
disease may produce either STa, heat-labile
toxin I, or both. STas from ETEC isolates are
related but distinct toxins (38). STh is produced
by strains of human origin, while STp is found
predominantly in porcine strains. The STa genes
(estA) of ETEC are encoded within a transpos-
able element and have been found on a variety of
replicons (39,40). STa is translated as a
precursor molecule of 72 amino acids and
undergoes two cleavage events before the
secretion of the mature form into the culture
supernatant. Mature STs are small peptides that
range from 17 to 53 amino acids. STh and STp
contain 19 and 18 residues, respectively. STas
share a conserved C-terminal region of 13 amino
acids essential for toxicity and the heat-stable
nature of the toxin. Six cysteine residues are
present within this domain, and the three
disulphide bonds formed between the cysteine
residues are necessary for toxicity of the
molecule. Binding of STa to its cellular receptor
results in the stimulation of membrane-bound
guanylate cyclase, which in turn leads to an
increase in intracellular cyclic GMP (Figure 1C)
(41). This increase in cyclic GMP affects
electrolyte flux in the bowel; sodium absorption
is inhibited and chloride secretion is stimulated.
These ion flux changes result in the secretory
diarrhea characteristic of ETEC infection. ETEC
cause travelers diarrhea and are a major source
of childhood diarrhea in many parts of the world.
The Nerve of Some Toxins
The C. botulinum neurotoxins (BoNTs,
serotypes A-G) and the C. tetani tetanus
neurotoxin (TeNT) constitute another category
of bacterial toxins on the basis of similarities in
structure, enzymatic activity, and the targeting
to cells of the nervous system. BoNTs are most
commonly associated with infant and foodborne
botulism and exist in nature as large complexes
comprised of the neurotoxin and one or more
associated proteins  believed to provide protection230 Emerging Infectious Diseases Vol. 5, No. 2, AprilJune 1999
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and stability to the toxin molecule while in the
gut (42,43). TeNT, which is synthesized from
vegetative C. tetani in wounds, does not appear
to form complexes with any other protein
components  (42,43).
The BoNTs and TeNT are either plasmid
encoded (TeNT, BoNTs/A, G, and possibly B) or
bacteriophage encoded (BoNTs/C, D, E, F), and
the neurotoxins are synthesized as inactive
polypeptides of 150 kDa (44). BoNTs and TeNT
are released from lysed bacterial cells and then
activated by the proteolytic cleavage of an
exposed loop in the neurotoxin polypeptide (45).
Each active neurotoxin molecule consists of a
heavy (100 kDa) and light chain (50 kDa) linked
by a single interchain disulphide bond (42,45).
The heavy chains of both the BoNTs and TeNT
contain two domains: a region necessary for
toxin translocation located in the N-terminal
half of the molecule, and a cell-binding domain
located within the C-terminus of the heavy chain
(45,46). The light chains of both the BoNTs and
TeNT contain zinc-binding motifs required for
the zinc-dependent protease activities of the
molecules (45,46).
The cellular targets of the BoNTs and TeNT
are a group of proteins required for docking and
fusion of synaptic vesicles to presynaptic plasma
membranes and therefore essential for the
release of neurotransmitters. The BoNTs bind to
receptors on the presynaptic membrane of motor
neurons associated with the peripheral nervous
system. Proteolysis of target proteins in these
neurons inhibits the release of acetylcholine,
thereby preventing muscle contraction (47,48).
BoNTs/B, D, F, and G cleave the vesicle-
associated membrane protein and synaptobrevin,
BoNT/A and E target the synaptosomal-
associated protein SNAP-25, and BoNT/C
hydrolyzes syntaxin and SNAP-25 (42,45,46).
TeNT affects the central nervous system and
does so by entering two types of neurons. TeNT
initially binds to receptors on the presynaptic
membrane of motor neurons but then migrates
by retrograde vesicular transport to the spinal
cord, where the neurotoxin can enter inhibitory
interneurons (45,47). Cleavage of the vesicle-
associated membrane protein and synaptobrevin
in these neurons disrupts the release of glycine
and gamma-amino-butyric acid, which, in turn,
induces muscle contraction (47,48). The con-
trasting clinical manifestations of BoNT or TeNT
intoxication (flaccid and spastic paralysis,
respectively) are the direct result of the specific
neurons affected and the type of neurotransmit-
ters blocked (45-47).
Bacterial Superantigens: Too Much of a
Good Thing
Several bacterial toxins can act directly on
the T cells and antigen-presenting cells of the
immune system. Impairment of the immunologic
functions of these cells by toxin can lead to
human disease. One large family of toxins in this
category are the pyrogenic toxin superantigens
(PTSAgs), whose hallmark biological activities
include potent stimulation of the immune cell
system, pyrogenicity, and enhancement of
endotoxin shock (49-51). These stable, secreted
toxins of 22 kDa to 30 kDa include staphylococcal
enterotoxins serotypes A-E, G, and H; group A
streptococcal pyrogenic exotoxins serotypes A-C
and F; group A streptococcal superantigen; and
staphylococcal TSST-1, which we discuss below.
All PTSAgs share common biological activi-
ties, but TSST-1 is the most divergent member of
the toxin family, with less than 30% amino acid
homology to other family members (52-54).
TSST-1 is chromosomally encoded, and the tst
gene is located in a variable genetic element
in  S. aureus (49,52,55). The toxin is synthesized
as a precursor molecule of 234 residues with the
first 40 amino acids acting as a signal sequence
that is cleaved to generate the mature 22 kDa
toxin (49). Expression of TSST-1 depends on
oxygen, temperature, pH and glucose levels, and
is regulated by the S. aureus agr locus (49,51).
On the basis of crystallographic analysis, TSST-
1 appears structurally similar to several other
PTSAgs in that the toxin consists of two distinct
domains; however, unlike other family members,
TSST-1 does not require a zinc cofactor (51-54).
Domain A of TSST-1 (amino acid residues 1-17
and 90-194) exists as a ß-grasp motif, and domain
B consists of a five-stranded ß-barrel motif that
forms an oligosaccharide/oligonucleotide bind-
ing fold.
In general, the potent immunostimulatory
properties of PTSAgs are a direct result of toxin
binding to distinct regions outside the peptide
binding cleft of the major histocompatibility class
II molecules (expressed on the surface of
antigen-presenting cells) and to specific
Vß elements on the T-cell receptor. In particular,
the domain B of TSST-1 binds primarily to the
a-chain of human leukocyte antigen-DR1231 Vol. 5, No. 2, AprilJune 1999 Emerging Infectious Diseases
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molecules, while domain A specifically binds to
human T-cell receptor Vß2 elements (51-53,56).
Binding of TSST-1 to Vß2 T-cell receptor
elements results in a massive proliferation of up
to 20% of peripheral T cells, an event that
drastically skews the T-cell Vß repertoire
(53,56). T cells that undergo this expansion can
subsequently exist in a state of anergy or
undergo apoptosis (56). Concomitant to T-cell
proliferation is a massive release of both
lymphocyte (interleukin [IL]-2, tumor necrosis
factor ß, gamma interferon)-derived and mono-
cyte (IL-1, IL-6, tumor necrosis factor a)-derived
cytokines (51,56). These cytokines serve as
mediators of the hypotension, high fever, and
diffuse erythematous rash that are characteris-
tic of toxic-shock syndrome. Long established as
a key substance in causing staphylococcal toxic-
shock syndrome, TSST-1 has more recently been
linked with Kawasaki syndrome, a leading cause
of acquired heart disease in children in the
United States (50,54).
Dr. Jekyll or Mr. Hyde?
Some of these powerful disease-causing
toxins have been exploited to further basic
knowledge of cell biology or for medical purposes.
For example, cholera toxin and the related labile-
toxin of E. coli, as well as B. pertussis toxin, have
been used as biologic tools to understand the
mechanism of adenylate cyclase activation and
the role of cyclic AMP as a second messenger in
the eukaryotic cell (57-59). Derivatives of some of
these toxins, cholera toxin and labile toxin, have
also been incorporated into human vaccines
because of the adjuvant properties of these
molecules (60,61).
Similarly, the activities of several potent
cytotoxins have been harnessed as potential
therapies for certain cancers. Such toxins can
either be used directly in treatment or as
components of immunotoxins (62-64). For
example, Stx binds to the cell surface glycolipid
CD77, which is expressed by B cells in certain
B-cell lymphomas (65,66). This finding led to
studies that showed that Stx can purge murine
(and potentially human) bone marrow of
malignant CD77+ B cells before an autologous
bone marrow transplant (67). Other toxins that
inhibit protein synthesis, such as diphtheria
toxin, Pseudomonas exotoxin A, or the plant
toxin ricin, are frequently engineered as the cell-
killing component of immunotoxins. These
magic bullets, hybrids of the enzymatically
active portion of a toxin molecule and monoclonal
antibodies (or a receptor), are in clinical trials for
the treatment of persons with B-cell lymphomas,
leukemia, and bone marrow transplants.
Several clinical applications have also been
found for the powerful botulinum neurotoxin
type A (BoNT/A) (46,68). The disorders that
respond to BoNT/A involve muscle hyperactivity.
A minuscule amount of purified toxin injected
into specific sites results in paralysis of the
target muscle and ablation of the muscle spasm.
Therapy must be continual since the effect of the
toxin usually lasts for no more than several
months. The first maladies treated with BoNT/A
were eye movement abnormalities (69). How-
ever, the therapeutic value of BoNT/A has been
shown for many other disorders including
cervical and laryngeal dystonia, writers cramp,
hemifacial spasm, tremors, and tics (46,68). BoNT/
A is also used cosmetically to reduce deep
wrinkles caused by the contraction of facial
muscles (70).
Another toxic bacterial product with medical
applications is streptokinase, a potent plasmino-
gen activator produced by several pathogenic
streptococcal strains. The proteolytic activity of
streptokinase is used to clear blocked arteries in
patients who have heart attacks (71,72).
Vaccinate, Don’t Procrastinate
Vaccines directed at the toxic component of
bacterial pathogens have proven quite effective
in preventing certain diseases. Most licensed
toxoid vaccines are relatively crude, but
effective, preparations. These vaccines consist of
partially purified toxin preparations obtained
from culture supernatants of bacteria such as
C. diphtheriae, C. tetani, or B. anthracis.
Formaldehyde treatment is used to detoxify the
diphtheria and tetanus toxins for vaccine
formulation. The anthrax vaccine contains the
protective antigen and small amounts of the
lethal factor and edema factor toxins. The
current botulinum vaccine is an investigational
drug composed of crude preparations of five
botulinum toxoids and is distributed by the
Centers for Disease Control and Prevention to
researchers that work with the toxin or
organism. Acellular pertussis vaccines that
contain pertussis toxoid, alone or as one of
several components, are as effective as killed
whole-cell vaccines but less reactogenic (73);232 Emerging Infectious Diseases Vol. 5, No. 2, AprilJune 1999
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such vaccines have recently been approved for
use in infants as well as older children.
New vaccines aimed at toxins are in various
stages of development: research and develop-
ment, preclinical, phase I, phase II, or phase III
(74). The next generation of toxoid vaccines falls
into three general categories: purified toxoids
that have been inactivated by chemical or
genetic means; live, attenuated strains of the
causative agent that produce a genetically
derived toxoid; or live, attenuated unrelated
bacterial vector strains, such as V. cholerae or
Salmonella, that produce the target toxoid.
Examples of each of these approaches and
progress in development of specific toxoid
vaccines are described annually in the Jordan
Report (74).
Antitoxins raised against diphtheria, teta-
nus, and botulinum toxoids have also been used
for many years to treat seriously ill patients.
Antiserum specific for the Stx toxins produced by
E. coli O157:H7 and other STEC is under
development for the treatment and prevention of
hemolytic uremic syndrome, a life-threatening
sequela of these infections.
Summary
Microbial toxins capable of interrupting or
hyperstimulating many essential functions and
pathways of eukaryotic cells have evolved along
with the carrier bacterium. Presumably these
toxins confer some benefit to the bacterium,
either during a stage of the host-parasite
interaction or in some environmental niche
encountered by the bacterium. Certain bacterial
toxins act on the target cell surface to irreparably
damage the cell membrane or alter normal
cellular signal transduction. Other toxins
exhibit enzymatic activity once the molecule has
gained access to the cytoplasm of the sensitive
cell by endocytosis. Yet other bacterial toxins act
by either turning off or locking on a normal host
cell function.
Although detrimental to the susceptible host
during an infection, the activities of several
bacterial toxins have been exploited as probes of
eukaryotic cellular pathways and for medicinal
applications. Thus, research on a microbial toxin
produced by an established, emerging, or
reemerging pathogen is likely to yield novel
information about the role of that toxin in disease
as well as the properties of host cells that are
subverted by the toxin.
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